Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study. (Q44616173)
Jump to navigation
Jump to search
scientific article published on 17 October 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study. |
scientific article published on 17 October 2012 |
Statements
Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study (English)
Christine Wolschke
Thomas Stübig
Ute Hegenbart
Marion Heinzelmann
York Hildebrandt
Djordje Atanackovic
Peter Dreger
Axel Zander
Nicolaus Kröger
17 October 2012